Based on these findings, we speculate that decreased Nur77 expression in palmitate-induced hepatic steatosis, coupled with increased G0S2 expression, represents a molecular mechanism connecting palmitate to NAFLD, which strengthens the emerging potential of Nur77 as a candidate for the treatment of obesity-associated NAFLD. The gene discussed is G0S2; the disease is metabolic dysfunction-associated steatotic liver disease.